Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price target to $36.00 ...

Piper Sandler downgraded Amphastar (AMPH) to Neutral from Overweight with a price target of $36, down from $66. The firm noted that shares of ...

Reports Q4 revenue $4.32B, consensus $4.08B. “We are pleased to have closed 2024 with record fourth quarter sales and Adjusted Diluted EPS, ...

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Amphastar Pharmaceuticals Inc (Symbol: AMPH) entered into oversold territory, hitting an RSI ...

Check the time stamp on this data. Updated AI-Generated Signals for Amphastar Pharmaceuticals Inc. (AMPH) available here: AMPH. Type a few symbols and Take a Trial. The signals for these will appear ...

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at ...

Detailed price information for Amphastar Pharma (AMPH-Q) from The Globe and Mail including charting and trades.

Ever wonder which ETFs do the best job at beating the benchmark index? This list is a good place to start.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...